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 The maturation of the tumor vasculature implies the recruitment of pericytes covering 
and protecting the endothelial tubes from a variety of stresses including anti-angiogenic 
drugs.  Mural cells also provide mature tumor blood vessels with the ability to either relax or 
contract in response to substances present in the tumor microenvironment. The observed 
cyclic alterations in tumor blood flow (TBF) and the associated deficit in chemotherapeutic 
drug delivery could arise from the influence of such vasomodulators.  
 To challenge this hypothesis, we focused our work on endothelin-1 (ET-1) which, 
besides its largely ubiquitous, autocrine effects on tumor cell growth, is a powerful 
vasoconstrictor. We first documented that an ETA receptor antagonist could induce the 
relaxation of microdissected tumor arterioles, and selectively and quantitatively increase TBF 
in experimental tumor models. We then combined dye staining of functional (perfused) 
vessels, fluorescent microspheres-based mapping and dynamic contrast enhanced-magnetic 
resonance imaging (DCE-MRI) to identify TBF heterogeneities and examine the reversibility 
of such phenomenon. We found that administration of ETA receptor antagonist could indeed 
acutely reduce the extent of underperfused tumor areas, thereby proving the key role of vessel 
tone variations in the TBF heterogeneities. Importantly, we also provided evidence that the 
ETA antagonist administration could, despite an increase in tumor interstitial fluid pressure, 
improve the access of the contrast agent used in DCE-MRI and of conventional 
chemotherapy to the tumor compartment. We showed that the combinatory administration of 
cyclophosphamide with the ETA antagonist led to a significant increase in tumor growth 
delay when using low doses of cyclophosphamide and even to the tumor control when higher 
doses were used (vs either treatment given separately).  
 In conclusion, we report here that tumor endogenous ET-1 production largely 
participates in the temporal and spatial variations in TBF and that ETA antagonist 
administration may wipe out such heterogeneities, thereby eliciting an adjuvant strategy to 
improve the delivery of chemotherapeutic drugs to the tumor. 
 
 
